## **AMENDMENTS TO THE SPECIFICATION**

Please replace paragraph [0036] at page 13 with the following amended paragraph:

[0036] Figure 15. DNA sequence of the *trans*-spliced product (lane 1, lower band shown in Figure 14) (SEQ ID NO: 64) (SEQ ID NOS:64 and 126) (3' end; SEQ ID NO:127) (5' end; SEQ ID NO:128). The DNA sequence indicates the presence of the F508 codon (CTT), exon 9 sequence is contiguous with exon 10 sequence, and the His tag sequence.

Please replace paragraph [0042] at page 14 with the following amended paragraph:

[0042] Figure 21. Important structural elements of DSPTM7 (SEQ ID NOS:69-73). The double splicing PTM has both 3' and 5' functional splice sites as well as binding domains.

Please replace paragraph [0066] at page 18 with the following amended paragraph:

[0066] Figure 44A. Detailed structure of the mouse factor VIII PTM containing normal mouse sequences for exons 16-26. BGH=bovine growth hormone 3' UTR (untranslated sequence); Binding Domain=125bp (SEQ ID NO:106); base changes to eliminate cryptic sites are circled:F5, F6, F7, F8=primer sites; spacer sequence (SEQ ID NO:107).

Please replace paragraph [0078] at page 19 with the following amended paragraph:

NY02:474460.1

## FILE NO.A31304-B-A-E 069906.0145 PATENT

[0078] Figure 52A. HPV-PTM 1 with 80 bp binding domain targeted to 3' ss at 409 (SEQ ID NOS: 115 and 116).

Please replace paragraph [0079] at page 19 with the following amended paragraph:

[0079] Figure 52B. HPV-PTM 2 with 149 bp binding domain targeted to 3' ss at 409 (SEQ ID NO:117).

Please replace the sequence listing with the substitute sequence listing submitted herewith.